Hypoglycemic effects of cyclo (His-Pro) in streptozotocin-induced diabetic rats

Kyung Soo Ra, Hyung Joo Suh, Jang Won Choi

Research output: Contribution to journalArticle

Abstract

The effects of Cyclo (His-Pro) (CHP), a cyclic dipeptide structurally related to thyrotropin-releasing hormone (TRH), on glucose metabolism, blood insulin level, lipid profile, and the viability of pancreatic cells were investigated in streptozotocin (STZ)-induced diabetic rats. The rats (Sprague-Dawley) with a blood glucose level above 300 mg/dL after induction with STZ (50 mg/kg of body weight) were considered to be diabetic and used for the treatment with CHP (4 mg/day/kg of body weight). The blood glucose level in the CHP-fed rats was reduced remarkably by approximately 56% as compared to the untreated diabetic group at 21 days of feeding. In an oral glucose tolerance test, blood glucose levels were restoredto baseline at 120 min after CHP treatment, although the levels increased significantly after 30 min. Plasma insulin levels in the CHP-treated group were also enhanced by 2-fold compared to the untreated group. Triglyceride and total cholesterol levels in CHP-treated rats almost returned to normal levels. Moreover, histological examination showed that CHP treatment restored impaired β-cells in the pancreas up to two-thirds of the normal level. The transcriptional level of C-reactive protein (CRP), used mainly as a marker of inflammation, was also restored mimicking normal level in the CHP-treated-group, suggesting that the β-cells destroyed by STZ were, at least in part, recovered. Accordingly, CHP was concluded to have an excellent hypoglycemic effect by lowering average plasma glucose levels, increasing insulin secretion, and restoring the viability of pancreatic β-cells in diabetic rats. We suggest that CHP might be a potential candidate to control Type I diabetes mellitus.

Original languageEnglish
Pages (from-to)176-184
Number of pages9
JournalBiotechnology and Bioprocess Engineering
Volume17
Issue number1
DOIs
Publication statusPublished - 2012 Feb 1

Fingerprint

Streptozocin
Hypoglycemic Agents
Glucose
Blood Glucose
Rats
Insulin
Blood
Cell Survival
Body Weight
Thyrotropin-Releasing Hormone
Dipeptides
Plasmas
Glucose Tolerance Test
Type 1 Diabetes Mellitus
C-Reactive Protein
Sprague Dawley Rats
Pancreas
Medical problems
Triglycerides
Metabolism

Keywords

  • Cyclo (His-Pro)
  • Diabetes
  • Hypoglycemic effect
  • Pancreatic β-cell
  • Streptozotocin

ASJC Scopus subject areas

  • Biotechnology
  • Applied Microbiology and Biotechnology
  • Biomedical Engineering
  • Bioengineering

Cite this

Hypoglycemic effects of cyclo (His-Pro) in streptozotocin-induced diabetic rats. / Ra, Kyung Soo; Suh, Hyung Joo; Choi, Jang Won.

In: Biotechnology and Bioprocess Engineering, Vol. 17, No. 1, 01.02.2012, p. 176-184.

Research output: Contribution to journalArticle

@article{2a74609e017747f78d5870eff43eee3b,
title = "Hypoglycemic effects of cyclo (His-Pro) in streptozotocin-induced diabetic rats",
abstract = "The effects of Cyclo (His-Pro) (CHP), a cyclic dipeptide structurally related to thyrotropin-releasing hormone (TRH), on glucose metabolism, blood insulin level, lipid profile, and the viability of pancreatic cells were investigated in streptozotocin (STZ)-induced diabetic rats. The rats (Sprague-Dawley) with a blood glucose level above 300 mg/dL after induction with STZ (50 mg/kg of body weight) were considered to be diabetic and used for the treatment with CHP (4 mg/day/kg of body weight). The blood glucose level in the CHP-fed rats was reduced remarkably by approximately 56{\%} as compared to the untreated diabetic group at 21 days of feeding. In an oral glucose tolerance test, blood glucose levels were restoredto baseline at 120 min after CHP treatment, although the levels increased significantly after 30 min. Plasma insulin levels in the CHP-treated group were also enhanced by 2-fold compared to the untreated group. Triglyceride and total cholesterol levels in CHP-treated rats almost returned to normal levels. Moreover, histological examination showed that CHP treatment restored impaired β-cells in the pancreas up to two-thirds of the normal level. The transcriptional level of C-reactive protein (CRP), used mainly as a marker of inflammation, was also restored mimicking normal level in the CHP-treated-group, suggesting that the β-cells destroyed by STZ were, at least in part, recovered. Accordingly, CHP was concluded to have an excellent hypoglycemic effect by lowering average plasma glucose levels, increasing insulin secretion, and restoring the viability of pancreatic β-cells in diabetic rats. We suggest that CHP might be a potential candidate to control Type I diabetes mellitus.",
keywords = "Cyclo (His-Pro), Diabetes, Hypoglycemic effect, Pancreatic β-cell, Streptozotocin",
author = "Ra, {Kyung Soo} and Suh, {Hyung Joo} and Choi, {Jang Won}",
year = "2012",
month = "2",
day = "1",
doi = "10.1007/s12257-011-0618-1",
language = "English",
volume = "17",
pages = "176--184",
journal = "Biotechnology and Bioprocess Engineering",
issn = "1226-8372",
publisher = "Korean Society for Biotechnology and Bioengineering",
number = "1",

}

TY - JOUR

T1 - Hypoglycemic effects of cyclo (His-Pro) in streptozotocin-induced diabetic rats

AU - Ra, Kyung Soo

AU - Suh, Hyung Joo

AU - Choi, Jang Won

PY - 2012/2/1

Y1 - 2012/2/1

N2 - The effects of Cyclo (His-Pro) (CHP), a cyclic dipeptide structurally related to thyrotropin-releasing hormone (TRH), on glucose metabolism, blood insulin level, lipid profile, and the viability of pancreatic cells were investigated in streptozotocin (STZ)-induced diabetic rats. The rats (Sprague-Dawley) with a blood glucose level above 300 mg/dL after induction with STZ (50 mg/kg of body weight) were considered to be diabetic and used for the treatment with CHP (4 mg/day/kg of body weight). The blood glucose level in the CHP-fed rats was reduced remarkably by approximately 56% as compared to the untreated diabetic group at 21 days of feeding. In an oral glucose tolerance test, blood glucose levels were restoredto baseline at 120 min after CHP treatment, although the levels increased significantly after 30 min. Plasma insulin levels in the CHP-treated group were also enhanced by 2-fold compared to the untreated group. Triglyceride and total cholesterol levels in CHP-treated rats almost returned to normal levels. Moreover, histological examination showed that CHP treatment restored impaired β-cells in the pancreas up to two-thirds of the normal level. The transcriptional level of C-reactive protein (CRP), used mainly as a marker of inflammation, was also restored mimicking normal level in the CHP-treated-group, suggesting that the β-cells destroyed by STZ were, at least in part, recovered. Accordingly, CHP was concluded to have an excellent hypoglycemic effect by lowering average plasma glucose levels, increasing insulin secretion, and restoring the viability of pancreatic β-cells in diabetic rats. We suggest that CHP might be a potential candidate to control Type I diabetes mellitus.

AB - The effects of Cyclo (His-Pro) (CHP), a cyclic dipeptide structurally related to thyrotropin-releasing hormone (TRH), on glucose metabolism, blood insulin level, lipid profile, and the viability of pancreatic cells were investigated in streptozotocin (STZ)-induced diabetic rats. The rats (Sprague-Dawley) with a blood glucose level above 300 mg/dL after induction with STZ (50 mg/kg of body weight) were considered to be diabetic and used for the treatment with CHP (4 mg/day/kg of body weight). The blood glucose level in the CHP-fed rats was reduced remarkably by approximately 56% as compared to the untreated diabetic group at 21 days of feeding. In an oral glucose tolerance test, blood glucose levels were restoredto baseline at 120 min after CHP treatment, although the levels increased significantly after 30 min. Plasma insulin levels in the CHP-treated group were also enhanced by 2-fold compared to the untreated group. Triglyceride and total cholesterol levels in CHP-treated rats almost returned to normal levels. Moreover, histological examination showed that CHP treatment restored impaired β-cells in the pancreas up to two-thirds of the normal level. The transcriptional level of C-reactive protein (CRP), used mainly as a marker of inflammation, was also restored mimicking normal level in the CHP-treated-group, suggesting that the β-cells destroyed by STZ were, at least in part, recovered. Accordingly, CHP was concluded to have an excellent hypoglycemic effect by lowering average plasma glucose levels, increasing insulin secretion, and restoring the viability of pancreatic β-cells in diabetic rats. We suggest that CHP might be a potential candidate to control Type I diabetes mellitus.

KW - Cyclo (His-Pro)

KW - Diabetes

KW - Hypoglycemic effect

KW - Pancreatic β-cell

KW - Streptozotocin

UR - http://www.scopus.com/inward/record.url?scp=84861053885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861053885&partnerID=8YFLogxK

U2 - 10.1007/s12257-011-0618-1

DO - 10.1007/s12257-011-0618-1

M3 - Article

AN - SCOPUS:84861053885

VL - 17

SP - 176

EP - 184

JO - Biotechnology and Bioprocess Engineering

JF - Biotechnology and Bioprocess Engineering

SN - 1226-8372

IS - 1

ER -